Odronextamab, which is designed to bridge CD20-expressing cancer cells with CD3-positive T cells to trigger an immune ...

“Our positive results in animals with ongoing disease raise the possibility that oral anti-CD3 antibodies might be an effective immunomodulatory therapy for SLE that could be easily and rapidly ...

CD20 × CD3 bispecific antibodies bind to both CD20 on malignant B cells and CD3 on T cells, bringing them into close proximity, which triggers T cell-mediated killing of the targeted B cells.